 | • レポートコード：MRC23Q37432 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、87ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のインフルエンザ菌b型混合ワクチン市場について調査・分析し、世界のインフルエンザ菌b型混合ワクチン市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（バイアル、プレフィルド）、用途別セグメント分析（病院、地域医療サービスセンター、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Bharat Biotech、Glaxosmithkline、Biokangtai、Lanzhou Institute、Olymvax、Sanofi Pasteur、Walvax Biotechnology、Zhifei Biologicalなどが含まれています。世界のインフルエンザ菌b型混合ワクチン市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、インフルエンザ菌b型混合ワクチン市場規模を推定する際に考慮しました。本レポートは、インフルエンザ菌b型混合ワクチンの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、インフルエンザ菌b型混合ワクチンに関するビジネス上の意思決定に役立てることを目的としています。 ・インフルエンザ菌b型混合ワクチン市場の概要 - 製品の定義 - インフルエンザ菌b型混合ワクチンのタイプ別セグメント - 世界のインフルエンザ菌b型混合ワクチン市場規模：タイプ別分析（バイアル、プレフィルド） - インフルエンザ菌b型混合ワクチンの用途別セグメント - 世界のインフルエンザ菌b型混合ワクチン市場規模：用途別分析（病院、地域医療サービスセンター、その他） - 世界のインフルエンザ菌b型混合ワクチン市場規模予測（2018年-2029年） - インフルエンザ菌b型混合ワクチンの平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - インフルエンザ菌b型混合ワクチン市場の競争状況およびトレンド ・インフルエンザ菌b型混合ワクチンの地域別市場規模 - 北米のインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - アメリカのインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - ヨーロッパのインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - アジア太平洋のインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - 中国のインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - 日本のインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - 韓国のインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - インドのインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - オーストラリアのインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - 中南米のインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） - 中東・アフリカのインフルエンザ菌b型混合ワクチン市場規模（2018年-2029年） ・タイプ別セグメント：バイアル、プレフィルド - 世界のインフルエンザ菌b型混合ワクチンのタイプ別販売量（2018年-2023年） - 世界のインフルエンザ菌b型混合ワクチンのタイプ別売上（2018年-2023年） - 世界のインフルエンザ菌b型混合ワクチンのタイプ別価格 ・用途別セグメント：病院、地域医療サービスセンター、その他 - 世界のインフルエンザ菌b型混合ワクチンの用途別販売量（2018年-2023年） - 世界のインフルエンザ菌b型混合ワクチンの用途別売上（2018年-2023年） - 世界のインフルエンザ菌b型混合ワクチンの用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Bharat Biotech、Glaxosmithkline、Biokangtai、Lanzhou Institute、Olymvax、Sanofi Pasteur、Walvax Biotechnology、Zhifei Biological ・産業チェーンと販売チャネルの分析 - インフルエンザ菌b型混合ワクチン産業チェーン分析 - インフルエンザ菌b型混合ワクチンの主要原材料 - インフルエンザ菌b型混合ワクチンの販売チャネル - インフルエンザ菌b型混合ワクチンのディストリビューター - インフルエンザ菌b型混合ワクチンの主要顧客 ・インフルエンザ菌b型混合ワクチン市場ダイナミクス - インフルエンザ菌b型混合ワクチンの業界動向 - インフルエンザ菌b型混合ワクチン市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Haemophilus Influenzae Type b Conjugate Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Haemophilus Influenzae Type b Conjugate Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Haemophilus Influenzae Type b Conjugate Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Haemophilus Influenzae Type b Conjugate Vaccine include Bharat Biotech, Glaxosmithkline, Biokangtai, Lanzhou Institute, Olymvax, Sanofi Pasteur, Walvax Biotechnology and Zhifei Biological, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Haemophilus Influenzae Type b Conjugate Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Haemophilus Influenzae Type b Conjugate Vaccine.
The Haemophilus Influenzae Type b Conjugate Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Haemophilus Influenzae Type b Conjugate Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Haemophilus Influenzae Type b Conjugate Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Bharat Biotech
Glaxosmithkline
Biokangtai
Lanzhou Institute
Olymvax
Sanofi Pasteur
Walvax Biotechnology
Zhifei Biological
Segment by Type
Vials
Prefilled
Segment by Application
Hospitals
Community Health Service Center
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Haemophilus Influenzae Type b Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Haemophilus Influenzae Type b Conjugate Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Haemophilus Influenzae Type b Conjugate Vaccine Market Overview
1.1 Product Overview and Scope of Haemophilus Influenzae Type b Conjugate Vaccine
1.2 Haemophilus Influenzae Type b Conjugate Vaccine Segment by Type
1.2.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Vials
1.2.3 Prefilled
1.3 Haemophilus Influenzae Type b Conjugate Vaccine Segment by Application
1.3.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Community Health Service Center
1.3.4 Others
1.4 Global Haemophilus Influenzae Type b Conjugate Vaccine Market Size Estimates and Forecasts
1.4.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue 2018-2029
1.4.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales 2018-2029
1.4.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Haemophilus Influenzae Type b Conjugate Vaccine Market Competition by Manufacturers
2.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Haemophilus Influenzae Type b Conjugate Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Haemophilus Influenzae Type b Conjugate Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Haemophilus Influenzae Type b Conjugate Vaccine, Product Type & Application
2.7 Haemophilus Influenzae Type b Conjugate Vaccine Market Competitive Situation and Trends
2.7.1 Haemophilus Influenzae Type b Conjugate Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Haemophilus Influenzae Type b Conjugate Vaccine Players Market Share by Revenue
2.7.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Haemophilus Influenzae Type b Conjugate Vaccine Retrospective Market Scenario by Region
3.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Global Haemophilus Influenzae Type b Conjugate Vaccine Sales by Region: 2018-2029
3.2.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales by Region: 2018-2023
3.2.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales by Region: 2024-2029
3.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Region: 2018-2029
3.3.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Region: 2018-2023
3.3.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Region: 2024-2029
3.4 North America Haemophilus Influenzae Type b Conjugate Vaccine Market Facts & Figures by Country
3.4.1 North America Haemophilus Influenzae Type b Conjugate Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Haemophilus Influenzae Type b Conjugate Vaccine Sales by Country (2018-2029)
3.4.3 North America Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Haemophilus Influenzae Type b Conjugate Vaccine Market Facts & Figures by Country
3.5.1 Europe Haemophilus Influenzae Type b Conjugate Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Haemophilus Influenzae Type b Conjugate Vaccine Sales by Country (2018-2029)
3.5.3 Europe Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Haemophilus Influenzae Type b Conjugate Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Haemophilus Influenzae Type b Conjugate Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Haemophilus Influenzae Type b Conjugate Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Haemophilus Influenzae Type b Conjugate Vaccine Market Facts & Figures by Country
3.7.1 Latin America Haemophilus Influenzae Type b Conjugate Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Haemophilus Influenzae Type b Conjugate Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Haemophilus Influenzae Type b Conjugate Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Haemophilus Influenzae Type b Conjugate Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Haemophilus Influenzae Type b Conjugate Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales by Type (2018-2029)
4.1.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales by Type (2018-2023)
4.1.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales by Type (2024-2029)
4.1.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Type (2018-2029)
4.2.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Type (2018-2023)
4.2.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Type (2024-2029)
4.2.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales by Application (2018-2029)
5.1.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales by Application (2018-2023)
5.1.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales by Application (2024-2029)
5.1.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Application (2018-2029)
5.2.1 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Application (2018-2023)
5.2.2 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue by Application (2024-2029)
5.2.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Haemophilus Influenzae Type b Conjugate Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bharat Biotech
6.1.1 Bharat Biotech Corporation Information
6.1.2 Bharat Biotech Description and Business Overview
6.1.3 Bharat Biotech Haemophilus Influenzae Type b Conjugate Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bharat Biotech Haemophilus Influenzae Type b Conjugate Vaccine Product Portfolio
6.1.5 Bharat Biotech Recent Developments/Updates
6.2 Glaxosmithkline
6.2.1 Glaxosmithkline Corporation Information
6.2.2 Glaxosmithkline Description and Business Overview
6.2.3 Glaxosmithkline Haemophilus Influenzae Type b Conjugate Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Glaxosmithkline Haemophilus Influenzae Type b Conjugate Vaccine Product Portfolio
6.2.5 Glaxosmithkline Recent Developments/Updates
6.3 Biokangtai
6.3.1 Biokangtai Corporation Information
6.3.2 Biokangtai Description and Business Overview
6.3.3 Biokangtai Haemophilus Influenzae Type b Conjugate Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Biokangtai Haemophilus Influenzae Type b Conjugate Vaccine Product Portfolio
6.3.5 Biokangtai Recent Developments/Updates
6.4 Lanzhou Institute
6.4.1 Lanzhou Institute Corporation Information
6.4.2 Lanzhou Institute Description and Business Overview
6.4.3 Lanzhou Institute Haemophilus Influenzae Type b Conjugate Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Lanzhou Institute Haemophilus Influenzae Type b Conjugate Vaccine Product Portfolio
6.4.5 Lanzhou Institute Recent Developments/Updates
6.5 Olymvax
6.5.1 Olymvax Corporation Information
6.5.2 Olymvax Description and Business Overview
6.5.3 Olymvax Haemophilus Influenzae Type b Conjugate Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Olymvax Haemophilus Influenzae Type b Conjugate Vaccine Product Portfolio
6.5.5 Olymvax Recent Developments/Updates
6.6 Sanofi Pasteur
6.6.1 Sanofi Pasteur Corporation Information
6.6.2 Sanofi Pasteur Description and Business Overview
6.6.3 Sanofi Pasteur Haemophilus Influenzae Type b Conjugate Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sanofi Pasteur Haemophilus Influenzae Type b Conjugate Vaccine Product Portfolio
6.6.5 Sanofi Pasteur Recent Developments/Updates
6.7 Walvax Biotechnology
6.6.1 Walvax Biotechnology Corporation Information
6.6.2 Walvax Biotechnology Description and Business Overview
6.6.3 Walvax Biotechnology Haemophilus Influenzae Type b Conjugate Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Walvax Biotechnology Haemophilus Influenzae Type b Conjugate Vaccine Product Portfolio
6.7.5 Walvax Biotechnology Recent Developments/Updates
6.8 Zhifei Biological
6.8.1 Zhifei Biological Corporation Information
6.8.2 Zhifei Biological Description and Business Overview
6.8.3 Zhifei Biological Haemophilus Influenzae Type b Conjugate Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Zhifei Biological Haemophilus Influenzae Type b Conjugate Vaccine Product Portfolio
6.8.5 Zhifei Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Haemophilus Influenzae Type b Conjugate Vaccine Industry Chain Analysis
7.2 Haemophilus Influenzae Type b Conjugate Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Haemophilus Influenzae Type b Conjugate Vaccine Production Mode & Process
7.4 Haemophilus Influenzae Type b Conjugate Vaccine Sales and Marketing
7.4.1 Haemophilus Influenzae Type b Conjugate Vaccine Sales Channels
7.4.2 Haemophilus Influenzae Type b Conjugate Vaccine Distributors
7.5 Haemophilus Influenzae Type b Conjugate Vaccine Customers
8 Haemophilus Influenzae Type b Conjugate Vaccine Market Dynamics
8.1 Haemophilus Influenzae Type b Conjugate Vaccine Industry Trends
8.2 Haemophilus Influenzae Type b Conjugate Vaccine Market Drivers
8.3 Haemophilus Influenzae Type b Conjugate Vaccine Market Challenges
8.4 Haemophilus Influenzae Type b Conjugate Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
